Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the ...
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, presented initial biomarker data demonstrating successful target engagement of CBL-B in its ongoing Phase 1 clinical trial with oral dosing of NX-1607
Biomarker results are a positive demonstration of target engagement for this first-in-class CBL-B inhibitor
Biomarker levels achieved with NX-1607 treatment correspond to levels associated with potent anti-tumor activity in disease models
SAN FRANCISCO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, presented initial biomarker data demonstrating successful target engagement of CBL-B in its ongoing Phase 1 clinical trial with oral dosing of NX-1607. These data are being presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which is being held November 8 – 12th in Boston.
“We are particularly encouraged by these initial biomarker data from the Phase 1 trial of NX-1607 measured in patients with advanced malignancies, which demonstrate remarkable concordance with levels observed in preclinical studies that are associated with potent anti-tumor activity,” said Robert J. Brown, M.D., Nurix’s executive vice president of clinical development. “The proximal biomarker of CBL-B inhibition in activated T cells can be measured in whole blood and demonstrate dose-dependence in our clinical studies enabling us to assess target engagement in the clinic and guide our selection of an appropriate dose for further expansion of the trial.”
